The human immunodeficiency virus (HIV) enhancer element is important in the regulation of HIV gene expression. A number of cellular proteins have been demonstrated to bind to the NF-KB motifs in this element. The genes encoding several of these proteins, including members of the rel family and PRDII-BF1, have been cloned. We characterized the binding of proteins encoded by the human c-rel and PRDII-BF1 genes to HIV NF-KB motifs and related enhancer elements. Both the human c-rel protein and two proteins derived from the PRDII-BF1 gene by alternative splicing bound specifically to the HIV NF-KB motif and related enhancer elements found in the immunoglobulin kappa, class I major histocompatibility complex, and interleukin-2 receptor genes. To determine the role of these factors in regulating HIV gene expression, we fused the cDNAs encoding either of the two proteins derived by alternative splicing of the PRDII-BF1 gene or the c-rel gene to the DNA binding region of the yeast transcription factor GAL4. GAL4 binding sites were inserted in place of the native HIV enhancer sequences in an HIV long terminal repeat chloramphenicol acetyltransferase construct. Cotransfection of these constructs revealed that c-rel was a strong activator of basal HIV gene expression but did not result in synergistic effects in the presence of tat. PRDII-BF1-derived cDNAs did not result in stimulation of either basal or tat-induced activated gene expression. These results indicate that multiple enhancer binding proteins may potentially regulate HIV in both a positive and negative manner.
Human immunodeficiency virus (HIV) gene expression is regulated by a variety of different regulatory regions in the long terminal repeat (LTR), including the negative regulatory, enhancer, SP1, TATA, and TAR elements. In addition, the transactivator tat protein is critical for high levels of HIV gene expression (summarized in reference 24). A number of different cellular DNA-and RNA-binding proteins have been demonstrated to bind to these regions and regulate HIV gene expression in both a positive and negative manner (14) . One of these regions, the HIV enhancer, has been studied in great detail. This region contains two consensus NF-KB binding motifs which are critical for HIV gene expression when assayed in transfection assays (14, 15, 29) . The role of these sites in viral growth seems less critical (28) , but they appear to be important for high-level HIV gene expression in activated T lymphocytes (20) . A number of different cellular factors have been demonstrated to bind to these motifs, including NF-KB, EBP-1, KBF-1, HIVen86, H2TF1, and PRDII-BF1 (4, 6, 7, 11, 12, 13, 22, 25, 34, 37, 42) . However, which of these proteins serve as positive activators of HIV gene expression has not been elucidated.
Recently, the NF-KB proteins have been extensively characterized (1-3, 7, 16, 17, 26, 30) . The NF-KB protein family comprises a number of proteins with different kinetics of nuclear localization following T-cell activation. These proteins have in common amino-terminal DNA binding and dimerization domains which are highly homologous to similar domains found in products of the v-rel, c-rel, and Drosophila dorsal genes (7, 9, 10, 17, 19, 26, 30, 40) . NF-KB-related proteins of 50, 55, 65, 75, and 85 kDa which bind to NF-KB motifs in the interleukin-2 receptor (IL-2R) promoter have been characterized (7) . The p50 subunit of * Corresponding author.
NF-KB is capable of forming homodimers. In addition, different members of the NF-KB family form heterodimers or heterotetramers (3, 7, 26) , and one member, p65, complexes with a cytoplasmic inhibitory protein, IKB (1, 2, 16, 30, 33, 43) . It is not clear which members of the rel family are critical in the regulation of HIV enhancer function.
In addition to the rel family, the genes of another family of proteins which bind to the HIV enhancer motif have been characterized (4, 12, 32, 34) . One member of this group, known as MBP-1 or PRDII-BF1, encodes a 300-kDa cellular protein with two widely spaced zinc fingers (4, 12) . Each of these zinc finger domains is capable of binding to DNA recognition sequences with homology to NF-KB motifs (4, 12) . Though the expression of PRDII-BF1/MBP-1 RNA is inducible by phorbol ester and mitogen stimulation of cells, no functional role of these proteins in regulating gene expression or cellular growth properties has been reported (4, 12) .
In an attempt to determine the role of the PRDII-BF1 and human c-rel genes in regulating HIV gene expression, cDNAs encoding the binding domains of each of the proteins were expressed in bacteria and their binding specificities were determined. These unrelated proteins both bind specifically to the HIV NF-KB motifs and related motifs found in the immunoglobulin kappa (IgK), major histocompatibility complex (MHC) class I, and IL 2R enhancers (5, 8, 22, 37) . To determine their role in regulation of HIV gene expression, cDNAs encoding either c-rel, which encodes an 85-kDa protein (9), or genes encoding each of the spliced gene products of PRDII-BF1 (200-and 70-kDa proteins, respectively) were each fused to the DNA binding domain of the yeast protein GAL4 (35, 36 
MATERIALS AND METHODS
Cloning of PRDII-BF1 and c-rel. (i) PRDII-BF1. Oligo(dT) and random-primed HeLa cell lambda gtll cDNA expression libraries purchased from Clontech Laboratories Inc. were screened with ligated, nick-translated oligonucleotides corresponding to the wild-type or mutated HIV enhancer regions (38) . Inserts from positive phage were excised with EcoRI, cloned into pUC19, and characterized by restriction mapping and dideoxy sequencing. This resulted in the cloning of a partial cDNA encompassing the second binding domain of PRDII-BF1 (12) . A second round of screening using this partial cDNA as a probe led to the isolation of a fragment covering nucleotides 5641 to 9010. The same probe was also used to screen a lambda GEM 11 genomic library made from leukocytes. This screening resulted in the isolation of a clone covering nucleotides 417 to 6530. This portion of the coding region was not interrupted by introns. The remaining portion of the open reading frame of PRDII-BF1 (nucleotides 280 to 759) was amplified from HeLa cDNA by the polymerase chain reaction (PCR).
(ii) c-rel. PCR was used to amplify two fragments from the c-rel cDNA, and the fragments were fused at the unique EcoRV site at position 1010 in the c-rel cDNA sequence (10) .
PCR. cDNA was synthesized by hexamer priming 2 pug of poly(A)-selected HeLa RNA, using a Promega RiboClone kit under conditions recommended by manufacturer. PCRs were performed in a DNA Thermal Cycler, using reagents from a GeneAmp kit (Perkin Elmer-Cetus). For each reaction, 1/10 of the cDNA was used along with 50 pmol of primer in a total volume of 100 ,ul. Mixes were heated for 5 min at 94°C and then incubated for 40 cycles at 55°C for 1 min, at 72°C for 1 min, and at 94°C for 1 min; 2 jul from each reaction mix was then reamplified with at least one nesting primer. Products were analyzed on 5% polyacrylamide gels. Products were usually visible only after the second round of amplification.
PCR primers. Sequences of primers are shown in Fig. 1 . Bacterial expression. The first binding domain (amino acids 342 to 551) and the second binding domain (amino acids 2045 to 2406) of PRDII-BF1 were cloned in frame in pGEX-2T (Pharmacia). A BamHI-DraI (nucleotide 1539) fragment from the c-rel cDNA was cloned in frame into BamHI-SmaIcut pGEX-3X. Constructs and a control pGEX-2T without insert were transformed into Escherichia coli JM109. Cultures (500 ml) were grown to an optical density at 600 nm of 0.7 to 0.9 and induced with 0.4 mM isopropyl-3-D-thiogalactopyranoside (IPTG) for 3 h. Cells were pelleted and resuspended in 10 ml of phosphate-buffered saline (PBS) plus 1% Triton X-100 (Sigma). Cells were mildly sonicated, debris was pelleted, and the supernatant was incubated with 1 ml of glutathione-Sepharose for 90 min at 4°C (39) . The construct was cloned in pGEM7 downstream of the T7 polymerase promoter and was linearized with either Scal (site in pGEM7), XhoI (amino acid 1409), or BstXI (amino acid 926). The PRDII-BF1 A2 cDNA was cloned in pGEM2 downstream the SP6 polymerase promoter. This construct was linearized with Hindlll. The full-length c-rel cDNA was cloned into the SmaI site of pGEM4, linearized with HindIII, and transcribed with SP6 polymerase. The DNA templates were transcribed in vitro, using a commercial kit for RNA synthesis (Promega). RNA was in vitro translated with micrococcal nuclease-treated rabbit reticulocyte lysate in a 50-pul reaction volume as directed by the supplier (Promega) . For analysis of the translation products, proteins were labeled with [35S]methionine and a 5-pul aliquot was run on sodium dodecyl sulfate-8% polyacrylamide gels. After electrophoresis, the gels were dried and subject to autoradiography.
Eucaryotic expression and reporter constructs. To construct fusions of the DNA binding domain of GAL4 (35, 36) and PRDII-BF1 Al, an end-filled Eco 1091 (nucleotide 306)-XbaI (in the pGEM7 polylinker) fragment from the pGEM7 expression construct was joined to a HindIII-SmaI fragment containing the first 147 amino acids of GAL4 and inserted into the pDP18 expression vector. To construct fusions of GAL4 and PRDII-BF1 A2, an EcoRI (nucleotides 6433 to 9010) fragment was fused to the first 147 amino acids of GAL4 (HindIII-EcoRI) and inserted into pDP18 (20) . To construct fusions of GAL4 and c-rel, an NcoI-SmaI extending from the rel initiating methionine at nucleotide 126 to the end of the cDNA clone was isolated, fused to the first 147 amino acids of GAL4 (HindIII-NcoI), and inserted into A second set of mutated oligonucleotides was used to test the specificity of the binding in competition assays. In these oligonucleotides, the underlined sequences were mutated A to G, G to A, C to T, and T to C.
Protein extract was incubated with 1 ,ug of co-poly(dI-dC) (Pharmacia) in binding buffer (10 mM Tris-HCI [pH 7.4], 1 mM EDTA, 1 mM dithiothreitol, 5% glycerol, 50 mM NaCl) for 10 min. When competition assays were performed, the proteins were incubated for a further 10 min with 50 ng of unlabeled oligonucleotide. The labeled probe (50,000 cpm) was added to the mixture, and after 20 min of incubation at room temperature, the samples were loaded on a 4% polyacrylamide gel and electrophoresed in 0.25 x TBE (1x TBE is 89 mM Tris, 89 mM borate [pH 8.3] , and 1 mM EDTA).
Transfection assays. An HIV LTR CAT plasmid containing five GAL4 binding sites in place of the HIV enhancer region was transfected into HepG2 cells in the presence of constructs containing the DNA binding domain of GAL4 fused to either PRDII-BF1 Al, PRDII-BF1 A2, c-rel, or VP-16. The HepG2 cells were transfected at 40 to 50% confluence and maintained in 10% fetal bovine serum with penicillin and streptomycin. The cells were harvested at 48 h posttransfection, and CAT assays were performed as described previously (18) . RESULTS PRDII-BF1 yields multiple enhancer-binding proteins by alternative splicing. To characterize the role of PRDII-BF1 on HIV gene expression, we wanted to further characterize and isolate cDNAs encoding this protein. Southern analysis revealed that in addition to the major species hybridizing with the PRDII-BF1 DNA, a number of fainter species were detected ( Fig. 2A) . This finding is consistent with recent studies including chromosomal mapping of PRDII-BF1, which indicated the likelihood of related gene products (1Sa, 34) . Northern (RNA) analysis of HeLa cytoplasmic mRNA using a portion of the carboxyl terminus of PRDII-BF1 revealed that in addition to the previously described 9.1-kb full-length PRDII-BF1 RNA (4, 12) , several smaller mRNA species were routinely detected (Fig. 2) . To determine whether these different species were due to the presence of alternative splicing or due to degradation, PCR with a variety of different primers corresponding to different regions of PRDII-BF1 cDNA was performed.
Two cDNAs isolated by PCR analysis of HeLa cytoplasmic RNA revealed that they contained only the first or second zinc finger DNA binding domains of the PRDII-BF1 gene. A schematic of the PRDII-BF1 cDNA and two PCR A. - products known as Al and A2, which contained the first and second binding domains, respectively, are shown (Fig. 3) . The nucleotides indicated refer to those in the complete PRDII-BF1 cDNA (12) . The Al construct contained the same initiating methionine as PRDII-BF1, and removal of the second DNA binding domain by splicing resulted in a change in the reading frame with introduction of a stop codon at position 7339. The A2 construct contained a second initiating methionine in an alternative reading frame; the first DNA binding domain was removed by splicing, and the previously described PRDII-BFi reading frame was preserved from position 6394 to a stop codon at 8497. Northern analysis using either the amino or carboxy portion of PRDII-BF1 revealed that in addition to hybridizing to the 9.1-kb full-length PRDII-BF1 RNA, these probes hybridized selectively to different smaller RNA species, further indicating their specificity (data not shown). Sequence analysis of these cDNAs revealed potential open reading frames encoding proteins of 200 kDa (Al) and 70 kDa (A2). To further characterize these cDNAs, each was cloned downstream of either the SP6 or T7 promoter in pGEM-based vectors, in vitro transcribed, and translated with rabbit reticulocyte lysate. As predicted, these cDNAs yielded specific translation products of 200 kDa (Fig. 4A, lane 1) and 70 kDa (Fig.  4B, lane 1) , respectively. In addition, a human c-rel cDNA was isolated by PCR analysis and then in vitro transcribed and translated (9) . This c-rel cDNA yielded an 80-kDa translation product, in agreement with published reports (Fig. 4C, lane 1) .
PRDII-BF1 and c-rel bind specifically to NF-KB motifs in HIV and related enhancers. Previous data indicated that both the rel family (7, 17, 21, 26) and PRDII-BF1 (4, 12) bound to recognition elements with homology to the NF-KB binding motifs. To compare the binding of these proteins to related enhancer elements, gel retardation was performed with oligonucleotides corresponding to the HIV enhancer and related motifs in the IgK, MHC, and IL-2R genes (5, 8, 22, 29, 37) (Fig. 5) . Proteins containing either the first or second zinc finger binding domains of PRDII-BF1 or the amino end of c-rel were expressed as glutathione-S-transferase fusions in bacteria and purified by glutathione-agarose chromatography (39) . Gel retardations with these proteins were then performed (Fig. 6) .
Protein containing the first binding domain of the PRDII-BF1 gene bound with high affinity to both the HIV and MHC (29) (prox., proximal; dist., distal), IgK (37) , MHC class 1 (5, 22) , and IL-2Ra (8) enhancers are shown. enhancer sequences (Fig. 6A, lanes 2 and 6) but with lower affinity to the IgK and IL-2R sequences (Fig. 6A, lanes 4 and  8) . Protein containing the second PRDII-BF1 binding domain bound with high affinity to all four of the enhancer sequences (Fig. 6B, lanes 2, 4, 6, and 8 ). This finding indicated that these two zinc finger binding domains in PRDII-BF1 have different affinities for related enhancer sequences. Next we determined the ability of c-rel to bind to these same motifs. The c-rel protein bound with high affinity to the HIV and MHC enhancer sequences and with somewhat lesser affinity to the IgK and IL-2R sequences (Fig. 6C,  lanes 4 and 8) . These results indicate that both PRDII-BF1 and c-rel were capable of binding to related enhancer motifs.
To determine the specificity of binding by PRDII-BF1 and c-rel, gel retardation was performed with labeled MHC oligonucleotides and competition analysis was performed with unlabeled wild-type and mutated MHC oligonucleotides (Fig. 7) . Both the first (Fig. 7A, lane 2) (20) . Multiple copies of GAL4 binding sites were inserted in place of the enhancer sequences in an HIV LTR CAT plasmid for use as a reporter plasmid in cotransfection assays in both the presence and absence of tat (Fig. 8) . The HepG2 cell line was used in transfection assays because it contains low levels of several enhancer-binding proteins, including AP-2 (41) . Similar results were also seen in the Jurkat cells (data not shown). Neither GAL4/PRDII-BF1 cDNA fusions containing the Al protein (Fig. 8A, lanes 1 to 3) or the A2 protein (Fig. 8A, lanes 4 to 6) were capable of activating basal HIV gene expression. In fact, constructs containing the Al protein reproducibly gave lower levels of HIV gene expression with increasing amounts of transfected plasmid (Fig. 8A,  lane 3) . A GAL4/c-rel fusion reproducibly gave 10-to 15-fold stimulation of basal HIV gene expression (Fig. 8A, lanes 7 to   9) . The level of activation of the HIV LTR CAT construct by c-rel was nearly as high as seen with GAL4/VP-16 fusions (Fig. 8A, lanes 10 to 12) , which have been demonstrated to activate a variety of viral and cellular promoters (35, 36) .
These constructs were also tested in both the presence and absence of tat. Again GAL4/c-rel (Fig. 8B, lane 7) significantly activated HIV LTR basal gene expression compared with GAL4 (Fig. 8B, lane 1) , GAL4/A1 (Fig. 8B, lanes 3) , and GAL4/A2 (Fig. 8B, lane 5) . There was no significant difference in the level of activation with use of each of these constructs in the presence of tat (Fig. 8B, lanes 2, 4, 6 , and 8). These results demonstrated that c-rel-but not PRDII-BF1-derived proteins was a potent activator of basal HIV gene expression, though no synergy with tat activation was detected. Moreover, the specificity of c-rel activation of HIV was confirmed by the fact that GAL4/c-rel did not activate other promoter constructs containing multimerized GAL4 sites, including the well-characterized construct containing the E1B TATA box (28) (data not shown).
DISCUSSION
The cloning of genes encoding cellular factors which bind to important regulatory motifs in the HIV LTR is critical for understanding the mechanisms governing HIV gene expression. One regulatory region, the enhancer, has been the subject of intense investigation. This region extending between -108 and -80 in the HIV LTR contains two NF-KB motifs which are also found in a number of other viral and cellular enhancer elements, including those of the cytomegalovirus, simian virus 40, IgK, and IL-2R (summarized in reference 24). Mutagenesis of the HIV enhancer region results in decreases in both basal and tat-induced gene expression from the HIV LTR in a variety of different cell lines (15, 29) . NF-KB motif mutations inserted into proviral constructs do not result in defects in viral growth (27) , but a role for these motifs in HIV gene expression is seen in activated T cells (20) . This finding further substantiates the role of the enhancer element in the regulation of HIV gene expression.
A number of different cellular factors, including NF-KB (37), EBP-1 (11, 42) , H2TF1 (5, 6), KBF-1 (22) , and HIVen86 (13) , have been demonstrated to bind to NF-KB motifs. Recent studies indicate that NF-KB proteins, including HIVen86, comprise a family of proteins related to the proto-oncogene c-rel (1-3, 7, 16, 26, 30) . This family of proteins is evolutionarily conserved in that a rel-related protein known as dorsal is also found in Drosophila cells (40) . The genes encoding several of these rel-related proteins, including p50, p65, and p80, have been cloned and shown to be highly conserved in their amino-terminal DNA binding and dimerization domains (7, 9, 10, 17, 26, 30, 33) . Another cellular factor known as PRDII-BF1/MBP-1 also binds to NF-KB motifs (4, 12) . This 300-kDa protein contains two widely separated zinc finger binding domains, each of which bind to NF-KB motifs (4, 12) . Like the rel family, factors related to PRDII-BF1 have been identified in both human and rat tissues (32, 34) . These studies define two families of enhancer-binding proteins which bind to NF-KB and related enhancer motifs.
Since we noted that several mRNAs were detected on Northern blots with a PRDII-BF1 cDNA as a probe, we used PCR analysis of HeLa cytoplasmic RNA to determine whether alternative splicing of PRDII-BF1 gives rise to different enhancer-binding factors. We isolated two cDNAs encoding cellular proteins of 200 and 70 kDa which contain either of two zinc finger DNA binding domains. 
